There will be two significant Catalysts here that should deliver significant SH Value.
1 The MND Topline Data
2, The FDA granting Orphan Drug Designation
I will then consider the likelihood of a T/O as MT the CEO has disclosed that the current incumbent treatment is under FDA Review , if that MND Treatment has its FDA approval revoked , then the chance of Big Pharma Buying this one very swiftly is High .
@asx11 of all of the ASX Companies I have followed or invested in PAA is the most Undervalued and virtually invisible as the Promotion Historically has been extremely poor , up until November last year the company had not capitalised on any Scientific Progress.. 10 years worth of progress is only now stating to be recognized with any associated value $$$$$
There will be two significant Catalysts here that should deliver...
-
- There are more pages in this discussion • 162 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $91.22M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 20.5¢ | $174.5K | 841.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 458470 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 144453 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |